Melissa Lyle

Welcome! You are invited to join a webinar: AHA's National AL-Amyloidosis Patient to Provider Connection Forum. After registering, you will receive a confirmation email about joining the webinar. This dynamic event will bring together leading AL-Amyloidosis experts and powerful patient perspectives to strengthen and advance your understanding of the AL-Amyloidosis care pathway. What You’ll Le...

I’m excited to be speaking at the AHA’s National AL-Amyloidosis Patient-to-Provider Connection Forum March 12th! Hope you can join us!

🔗 to register: heart.zoom.us/meeting/regi...

#Amyloidosis #HeartHealth #AHAQI @americanheart.bsky.social

10.03.2025 17:32 — 👍 1    🔁 0    💬 0    📌 0

Incredibly proud of our 🫀transplant team!
#CardioSky #MedSky

29.01.2025 18:10 — 👍 1    🔁 0    💬 0    📌 0

Transthyretin amyloid #CMP : a paradigm for advancing precision medicine

Advances in knowledge in #transthyretin cardiac #amyloidosis and its specific Rx

#ATTR-CM #HFpEF #tafamidis #diflunisal #acoramidis #CardioEd

academic.oup.com/eurheartj/ad... @escardio.bsky.social @cardioobdoc.bsky.social

12.01.2025 21:53 — 👍 3    🔁 2    💬 0    📌 0

Amyloidosis and Heart Transplantation in a New Era Background The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor. Objectives We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amy...

Excited to share the ⁦‪@MayoClinic‬⁩ experience with #amyloid and🫀transplant
📌Post tx survival #amyloid = non-amyloid pts
📌⬇️ wait times for #amyloid after allocation change
📌⬇️ multi- organ tx with TTR targeted therapies

onlinelibrary.wiley.com/doi/10.1111/...

12.01.2025 20:44 — 👍 4    🔁 1    💬 1    📌 0